Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels

Journal of Infection

Volumn 63, Issue 1, 2011, Pages 48-53

  Komiya, Kosaku ^a,b   Ariga, Haruyuki ^a   Nagai, Hideaki ^a   Kurashima, Atsuyuki ^a   Shoji, Syunsuke ^a   Ishii, Hiroshi ^b   Nakajima, Yutsuki ^a  

^a TOKYO NATIONAL HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Interferon; Reversion; Tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; INTERFERON-GAMMA; JAPAN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 79959599082     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.05.006     Document Type: Article

References (16)

1. Mazurek M., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K., et al. Centers for disease C, prevention: updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States. MMWR Recomm Rep 2010, 2010(59):1-25.
2. Guideline for the use of Quantiferon TB-2G. Kekkaku 2006, 81:393-397.
3. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
4. Dyrhol-Riise A.M., Gran G., Wentzel-Larsen T., Blomberg B., Haanshuus C.G., Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010, 10:57.
5. Chee C.B., KhinMar K.W., Gan S.H., Barkham T.M., Pushparani M., Wang Y.T. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 2007, 175:282-287.
6. Goletti D., Parracino M.P., Butera O., Bizzoni F., Casetti R., Dainotto D., et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007, 8:5.
7. Ewer K., Millington K.A., Deeks J.J., Alvarez L., Bryant G., Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006, 174:831-839.
8. Chee C.B., KhinMar K.W., Gan S.H., Barkham T.M., Koh C.K., Shen L., et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010, 36:355-361.
9. Katiyar S.K., Sampath A., Bihari S., Mamtani M., Kulkarni H. Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:1146-1152.
10. Pai M., Joshi R., Bandyopadhyay M., Narang P., Dogra S., Taksande B., et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 2007, 35:98-103.
11. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360:528-534.
12. Hamilton C.D., Stout J.E., Goodman P.C., Mosher A., Menzies R., Schluger N.W., et al. Tuberculosis trials C: the value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis 2008, 12:1059-1064.
13. Aiken A.M., Hill P.C., Fox A., McAdam K.P., Jackson-Sillah D., Lugos M.D., et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006, 6:66.
14. Dheda K., Udwadia Z.F., Huggett J.F., Johnson M.A., Rook G.A. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005, 11:195-202.
15. Busse P.J., Mathur S.K. Age-related changes in immune function: effect on airway inflammation. J Allergy Clin Immunol 2010, 126:690-699.
16. Vree M., Huong N.T., Duong B.D., Sy D.N., Van L.N., Hung N.V., et al. Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int J Tuberc Lung Dis 2007, 11:392-397.